Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.73 Million USD | -21.27% |
| 2022 | -21.79 Million USD | 62.45% |
| 2021 | -48.33 Million USD | -111.06% |
| 2020 | -24.4 Million USD | 53.94% |
| 2019 | -38.87 Million USD | -68.68% |
| 2018 | -37.72 Million USD | 40.35% |
| 2017 | -37.36 Million USD | 62.09% |
| 2016 | -54.21 Million USD | -125.39% |
| 2015 | -59.47 Million USD | -24.66% |
| 2014 | -42.27 Million USD | -195.99% |
| 2013 | -34.57 Million USD | 31.5% |
| 2012 | -22.16 Million USD | -51.18% |
| 2011 | -16.32 Million USD | -146.29% |
| 2010 | -8.92 Million USD | -90.93% |
| 2009 | -3.48 Million USD | -24.97% |
| 2008 | -2.79 Million USD | -127.02% |
| 2007 | -1.23 Million USD | 29.97% |
| 2006 | -1.75 Million USD | 13.04% |
| 2005 | -1.98 Million USD | -113.71% |
| 2004 | -1.85 Million USD | 50.34% |
| 2003 | -879.24 Thousand USD | -23.83% |
| 2002 | -1.52 Million USD | 53.26% |
| 2001 | -3.19 Million USD | 36.04% |
| 2000 | -5.01 Million USD | 13.38% |
| 1999 | -5.7 Million USD | -171.82% |
| 1998 | -2.39 Million USD | 35.29% |
| 1997 | -3.65 Million USD | -61.9% |
| 1996 | -3.2 Million USD | 22.22% |
| 1995 | -2 Million USD | -50.0% |
| 1994 | -2.5 Million USD | -28.57% |
| 1993 | -1.6 Million USD | -75.0% |
| 1992 | -1.3 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.72 Million USD | 11.73% |
| 2024 Q1 | -6.48 Million USD | -42.89% |
| 2023 Q1 | -6.51 Million USD | -9.43% |
| 2023 Q4 | -6.18 Million USD | 4.36% |
| 2023 Q2 | -4.7 Million USD | 27.76% |
| 2023 Q3 | -6.46 Million USD | -37.52% |
| 2023 FY | - USD | -21.27% |
| 2022 FY | - USD | 62.45% |
| 2022 Q3 | -4.82 Million USD | -44.12% |
| 2022 Q4 | -5.95 Million USD | -23.34% |
| 2022 Q1 | -5.7 Million USD | 78.47% |
| 2022 Q2 | -3.34 Million USD | 41.26% |
| 2021 Q3 | -4.24 Million USD | 47.12% |
| 2021 FY | - USD | -111.06% |
| 2021 Q4 | -26.46 Million USD | -523.24% |
| 2021 Q1 | -14.04 Million USD | -44.72% |
| 2021 Q2 | -8.03 Million USD | 42.82% |
| 2020 Q3 | -4.44 Million USD | -6.51% |
| 2020 FY | - USD | 53.94% |
| 2020 Q1 | -6.68 Million USD | 13.6% |
| 2020 Q4 | -9.7 Million USD | -118.19% |
| 2020 Q2 | -4.17 Million USD | 37.51% |
| 2019 Q1 | -58.43 Million USD | -335.85% |
| 2019 Q3 | 2.4 Million USD | -79.5% |
| 2019 Q4 | -7.73 Million USD | -421.76% |
| 2019 FY | - USD | -68.68% |
| 2019 Q2 | 11.72 Million USD | 120.07% |
| 2018 Q3 | -86.26 Million USD | -558.11% |
| 2018 FY | - USD | 40.35% |
| 2018 Q1 | 41.66 Million USD | -29.22% |
| 2018 Q4 | 24.77 Million USD | 128.72% |
| 2018 Q2 | -13.1 Million USD | -131.46% |
| 2017 Q1 | -72.18 Million USD | -278.29% |
| 2017 FY | - USD | 62.09% |
| 2017 Q4 | 58.86 Million USD | 258.63% |
| 2017 Q2 | -2.57 Million USD | 96.43% |
| 2017 Q3 | -37.1 Million USD | -1341.57% |
| 2016 Q4 | -19.08 Million USD | 61.5% |
| 2016 Q1 | -22.01 Million USD | -9.61% |
| 2016 Q2 | -48.67 Million USD | -121.08% |
| 2016 Q3 | -49.57 Million USD | -1.85% |
| 2016 FY | - USD | -125.39% |
| 2015 Q1 | -11.92 Million USD | 17.21% |
| 2015 Q2 | -11.93 Million USD | -0.06% |
| 2015 Q4 | -20.08 Million USD | -29.36% |
| 2015 FY | - USD | -24.66% |
| 2015 Q3 | -15.52 Million USD | -30.11% |
| 2014 Q2 | -11.42 Million USD | -20.24% |
| 2014 Q3 | -10.49 Million USD | 8.14% |
| 2014 Q4 | -14.4 Million USD | -37.21% |
| 2014 Q1 | -9.5 Million USD | -231.47% |
| 2014 FY | - USD | -195.99% |
| 2013 Q3 | -9.39 Million USD | -28.14% |
| 2013 Q2 | -7.33 Million USD | 3.79% |
| 2013 Q1 | -7.62 Million USD | -8.04% |
| 2013 FY | - USD | 31.5% |
| 2013 Q4 | 7.22 Million USD | 176.92% |
| 2012 Q2 | -5.47 Million USD | -10.36% |
| 2012 Q1 | -4.96 Million USD | 0.24% |
| 2012 FY | - USD | -51.18% |
| 2012 Q3 | -5.22 Million USD | 4.65% |
| 2012 Q4 | -7.05 Million USD | -35.1% |
| 2011 Q3 | -3.5 Million USD | 19.49% |
| 2011 Q1 | -3.66 Million USD | -8.95% |
| 2011 Q2 | -4.35 Million USD | -18.76% |
| 2011 Q4 | -4.97 Million USD | -41.85% |
| 2011 FY | - USD | -146.29% |
| 2010 Q3 | 110.94 Thousand USD | 105.21% |
| 2010 Q1 | -1.31 Million USD | -176.07% |
| 2010 FY | - USD | -90.93% |
| 2010 Q2 | -2.12 Million USD | -61.74% |
| 2010 Q4 | -3.36 Million USD | -3135.18% |
| 2009 Q1 | -904.17 Thousand USD | 5.78% |
| 2009 Q2 | -1.1 Million USD | -21.79% |
| 2009 Q4 | 1.72 Million USD | 158.85% |
| 2009 Q3 | -2.93 Million USD | -166.9% |
| 2009 FY | - USD | -24.97% |
| 2008 Q4 | -959.61 Thousand USD | -5.01% |
| 2008 Q1 | -356.66 Thousand USD | -38.57% |
| 2008 Q3 | -913.85 Thousand USD | -5.17% |
| 2008 Q2 | -868.96 Thousand USD | -143.64% |
| 2008 FY | - USD | -127.02% |
| 2007 Q4 | -257.39 Thousand USD | -73.19% |
| 2007 Q2 | -286.29 Thousand USD | 43.63% |
| 2007 Q1 | -507.9 Thousand USD | -49.33% |
| 2007 FY | - USD | 29.97% |
| 2007 Q3 | -148.61 Thousand USD | 48.09% |
| 2006 Q2 | -632.3 Thousand USD | -37.57% |
| 2006 Q4 | -340.12 Thousand USD | -59.66% |
| 2006 Q3 | -213.03 Thousand USD | 66.31% |
| 2006 Q1 | -459.6 Thousand USD | 0.28% |
| 2006 FY | - USD | 13.04% |
| 2005 FY | - USD | -113.71% |
| 2005 Q1 | -722.55 Thousand USD | -21.7% |
| 2005 Q2 | -425.72 Thousand USD | 41.08% |
| 2005 Q3 | -402.84 Thousand USD | 5.37% |
| 2005 Q4 | -460.91 Thousand USD | -14.42% |
| 2004 Q4 | -593.7 Thousand USD | -45.67% |
| 2004 Q1 | 518.74 Thousand USD | 483.45% |
| 2004 Q2 | -437.43 Thousand USD | -184.33% |
| 2004 Q3 | -407.56 Thousand USD | 6.83% |
| 2004 FY | - USD | 50.34% |
| 2003 Q1 | -311.02 Thousand USD | 32.79% |
| 2003 FY | - USD | -23.83% |
| 2003 Q3 | -141.98 Thousand USD | -277.94% |
| 2003 Q2 | -299.41 Thousand USD | 2.17% |
| 2003 Q4 | -126.81 Thousand USD | 88.24% |
| 2002 Q3 | 9419.00 USD | 101.63% |
| 2002 Q4 | -462.79 Thousand USD | -5013.38% |
| 2002 FY | - USD | 53.26% |
| 2002 Q1 | -424.4 Thousand USD | -121.75% |
| 2002 Q2 | -578.74 Thousand USD | -36.37% |
| 2001 Q2 | -1.1 Million USD | -18.12% |
| 2001 Q1 | -938.74 Thousand USD | 8.06% |
| 2001 Q3 | -916.1 Thousand USD | 17.38% |
| 2001 FY | - USD | 36.04% |
| 2001 Q4 | -191.38 Thousand USD | 79.11% |
| 2000 Q3 | -1.26 Million USD | 6.91% |
| 2000 FY | - USD | 13.38% |
| 2000 Q1 | -1.36 Million USD | 6.34% |
| 2000 Q2 | -1.35 Million USD | 0.5% |
| 2000 Q4 | -1.02 Million USD | 19.37% |
| 1999 Q2 | -1.1 Million USD | -37.5% |
| 1999 Q1 | -800 Thousand USD | 0.0% |
| 1999 FY | - USD | -171.82% |
| 1999 Q4 | -1.45 Million USD | 36.53% |
| 1999 Q3 | -2.39 Million USD | -109.09% |
| 1998 Q1 | -1.3 Million USD | -44.44% |
| 1998 FY | - USD | 35.29% |
| 1998 Q3 | -1.2 Million USD | -50.0% |
| 1998 Q2 | -800 Thousand USD | 38.46% |
| 1997 FY | - USD | -61.9% |
| 1997 Q1 | -500 Thousand USD | 28.57% |
| 1997 Q4 | -900 Thousand USD | 25.0% |
| 1997 Q3 | -1.2 Million USD | 7.69% |
| 1997 Q2 | -1.3 Million USD | -160.0% |
| 1996 Q2 | -2.1 Million USD | -2200.0% |
| 1996 Q3 | -600 Thousand USD | 71.43% |
| 1996 Q4 | -700 Thousand USD | -16.67% |
| 1996 FY | - USD | 22.22% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q3 | -400 Thousand USD | 75.0% |
| 1995 Q4 | 100 Thousand USD | 150.0% |
| 1995 Q2 | -800 Thousand USD | -60.0% |
| 1995 Q1 | -500 Thousand USD | 28.57% |
| 1995 FY | - USD | -50.0% |
| 1994 Q1 | -200 Thousand USD | 33.33% |
| 1994 FY | - USD | -28.57% |
| 1994 Q3 | -500 Thousand USD | 28.57% |
| 1994 Q2 | -700 Thousand USD | -250.0% |
| 1994 Q4 | -700 Thousand USD | -40.0% |
| 1993 Q1 | -200 Thousand USD | 33.33% |
| 1993 Q3 | -300 Thousand USD | 25.0% |
| 1993 Q4 | -300 Thousand USD | 0.0% |
| 1993 FY | - USD | -75.0% |
| 1993 Q2 | -400 Thousand USD | -100.0% |
| 1992 Q2 | -400 Thousand USD | -300.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q4 | -300 Thousand USD | -50.0% |
| 1992 Q1 | -100 Thousand USD | 0.0% |
| 1992 Q3 | -200 Thousand USD | 50.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 21.924% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 38.04% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 51.627% |
| Azitra, Inc. | -10.67 Million USD | -131.73% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -202.359% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -260.419% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 13.521% |
| CEL-SCI Corporation | -27.56 Million USD | 10.259% |
| iBio, Inc. | -14.02 Million USD | -76.4% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -22.547% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | -8.359% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -78.255% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -415.271% |
| NanoViricides, Inc. | -7.75 Million USD | -218.844% |
| Oragenics, Inc. | -20.87 Million USD | -18.467% |
| BiomX Inc. | -22.81 Million USD | -8.407% |
| BiomX Inc. | -22.81 Million USD | -8.407% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 312.282% |
| Palatin Technologies, Inc. | -29.03 Million USD | 14.805% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 29.5% |